Defining and targeting residual virus on combined antiretroviral therapy

Melbourne, Australia, 20-25 July 2014 Therapeutic targeting of residual HIV following successful antiretroviral suppression represents a potential mechanism of HIV cure. This meeting report describes the findings of two eminent investigators speaking at a session of the 20th International Conference...

Full description

Saved in:
Bibliographic Details
Published inFuture virology Vol. 9; no. 9; pp. 791 - 793
Main Author Kevin Ward, Christopher James
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.09.2014
Subjects
Antiretroviral agents
Health aspects
Highly active antiretroviral therapy
Human immunodeficiency virus
Infection
Online AccessGet full text

Cover

More Information
Summary:Melbourne, Australia, 20-25 July 2014 Therapeutic targeting of residual HIV following successful antiretroviral suppression represents a potential mechanism of HIV cure. This meeting report describes the findings of two eminent investigators speaking at a session of the 20th International Conference of the International AIDS Society. This conference attracted approximately 14,000 delegates comprising patients, scientists, clinicians and other key stakeholders. Herein, two putative targets of novel therapy are described: the kick and kill approach offered by HDAC inhibitors and the use of bispecific antibodies to direct CD8 T-cell killing in germinal centers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1746-0794
1746-0808
DOI:10.2217/fvl.14.72